The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations.

J Am Acad Orthop Surg · Sep 01 2026 · Recent

Barton KI, Boyle RJ, Dennis DA, Jennings JM

From the Colorado Joint Replacement (Barton, Boyle, Dennis, DE

Adult Reconstruction

SUMMARY — THE REDUCTIONThis review examines perioperative implications, complications, and management considerations for GLP-1 receptor agonist use in total joint arthroplasty patients.
Abstract, as published

Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are used in diabetic patients for glycemic control. Yet, there has been a notable rise in their use for weight loss management in obese patients. This review critically appraises current evidence on perioperative implications of GLP-1 receptor agonists in TJA patients. The review discusses GLP-1 RA implications and use (physiology, pharmacology, pharmacodynamics, mechanisms of actions, and commonly used GLP-1 Ras), complications and adverse effects, considerations for the anesthesiologist, considerations for the TJA surgeon, and current clinical practice recommendations in 2025.

Featured in the 2026-09-02 issue.

← Hip arthroplasty following proximal femoral tumour resection …Hip Joint Capsular Anatomy, Mechanics, and Surgical Management. →

The Reduction is a free email digest of newly published orthopaedic literature — a handful of new papers in the subspecialties you choose, each summarized like this one. Subscribe free or browse the archive.